CN102861062A - Application of Houttuynoid C in endometrial cancer treatment medicine - Google Patents
Application of Houttuynoid C in endometrial cancer treatment medicine Download PDFInfo
- Publication number
- CN102861062A CN102861062A CN2012104183267A CN201210418326A CN102861062A CN 102861062 A CN102861062 A CN 102861062A CN 2012104183267 A CN2012104183267 A CN 2012104183267A CN 201210418326 A CN201210418326 A CN 201210418326A CN 102861062 A CN102861062 A CN 102861062A
- Authority
- CN
- China
- Prior art keywords
- houttuynoid
- application
- cancer treatment
- endometrial cancer
- treatment medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to application of Houttuynoid C in preparing endometrial cancer treatment medicine, which belongs to the technical field of new application of the medicine. According to the assessment on the antineoplastic activity through in-vitro MTT method, Houttuynoid C has an obvious inhibiting effect on the growth of human endometrium cancer cell strains ISK and RL95-2. Therefore, Houttuynoid C can be used for preparing the endometrial cancer treatment medicine, and has a favorable development and application prospect. The application of Houttuynoid C in preparing the endometrial cancer treatment medicine, which is provided by the invention, is disclosed for the first time, and because the skeleton type belongs to brand-new skeleton type, the inhibiting activity of Houttuynoid C to endometrium cancer cells is extremely strong.
Description
Technical field
The present invention relates to the new purposes of compound H outtuynoid C, relate in particular to the application of Houttuynoid C in the anti-endometrium cancer drug of preparation.
Technical background
Cancer is to one of disease of human life's health hazard maximum, and annual have a large amount of people to die from cancer.The research and development of cancer therapy drug are the focuses of study of pharmacy always.Having 74% to be the natural product or derivatives thereof in the antitumor drug, is exactly the present reasonable antitumor drug of effect clinically such as paclitaxel and derivant thereof.Therefore, searching anticancer compound or lead compound have great importance from natural product.
The compound H outtuynoid C that the present invention relates to is one and delivered (Chen in 2012, S. D. et al., 2012. Houttuynoid C_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.) New skeleton compound, this chemical compound has brand-new framework types, present purposes only relates to anti-herpes simplex virus activity (Chen, S. D. et al., 2012. Houttuynoid C_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.), belong to open first for the purposes of the Houttuynoid C that the present invention relates in preparation treatment endometrium cancer drug, because framework types belongs to brand-new framework types, and its inhibition for endometrial carcinoma cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for simultaneously carcinoma of endometrium obviously has significant progress.
Summary of the invention
The invention provides the application of compound H outtuynoid C in the preparation antitumor drug.
The present invention adopts following technical scheme: the application of Houttuynoid C in the anti-endometrium cancer drug of preparation, and the structural formula of Houttuynoid C is shown in formula I:
The present invention finds that by external MTT anti-tumor activity evaluation Houttuynoid C also has significant inhibitory action to the growth of people's Endometrial carcinoma cell line ISK and RL95-2, suppresses the IC of this 2 strain Growth of Cells
50Value is respectively 0.17 ± 0.07 μ M and 0.25 ± 0.06 μ M.Therefore, Houttuynoid C can for the preparation of anti-endometrium cancer drug, have good development prospect.
The purposes of the Houttuynoid C that the present invention relates in preparation treatment endometrium cancer drug belongs to open first, because framework types belongs to brand-new framework types, and its inhibition for endometrial carcinoma cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for simultaneously carcinoma of endometrium obviously has significant progress.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
The specific embodiment
The preparation method of compound H outtuynoid C involved in the present invention is referring to document (Chen, S. D. et al., 2012. Houttuynoid C_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
Embodiment 1: the preparation of compound H outtuynoid C tablet involved in the present invention:
Get 20 and digest compound Houttuynoid C, add conventional adjuvant 180 grams of preparation tablet, mixing, conventional tablet machine are made 1000.
Embodiment 2: the preparation of compound H outtuynoid C capsule involved in the present invention:
Get 20 and digest compound Houttuynoid C, add conventional adjuvant such as starch 180 grams of preparation capsule, mixing is encapsulatedly made 1000.
Further specify its pharmaceutically active below by pharmacodynamic experiment.
Experimental example: adopt mtt assay assessing compound Houttuynoid C to the growth inhibited effect of people's Endometrial carcinoma cell line
1. method: the cell that is in the growth logarithmic (log) phase: people's Endometrial carcinoma cell line ISK and RL95-2(buy from Chinese Academy of Sciences's cell bank) with 1.5 * 10
4The concentration kind is in 96 orifice plates.Suck original culture medium after cell culture 24 h are adherent.Test is divided into blank group, drug treating group.Blank group is changed 1640 culture medium that contain 10% hyclone; It is 100 μ M that the replacing of drug treating group contains concentration, 50 μ M, 10 μ M, 1 μ M, 0.1 μ M, the culture medium of the Houttuynoid C of 0.01 μ M and 0.001 μ M.After cultivating 48 h, add the MTT of concentration 5mg/mL, continue to be put in CO
2Incubator is cultivated 4 h, then suck 100 μ L supernatants along culture fluid top, add 100 μ L DMSO, 10 min are placed in the dark place, utilize microplate reader (Sunrise company product) to measure light absorption value (wavelength 570nm), and according to light absorption value calculating cell survival situation, 6 repeating holes are established in each processing.Cell survival rate (%)=Δ OD
Drug treating/ Δ OD
Blank* 100.
2. result: Houttuynoid C has significant inhibitory action to the growth of people's Endometrial carcinoma cell line ISK and RL95-2.This chemical compound suppresses the IC of people Endometrial carcinoma cell line ISK and RL95-2 growth
50Value is respectively: 0.17 ± 0.07 μ M and 0.25 ± 0.06 μ M.
Shown that by above-described embodiment Houttuynoid C of the present invention has good inhibitory action to the growth of people's Endometrial carcinoma cell line ISK and RL95-2.Prove that thus it is active that Houttuynoid C of the present invention has anti-carcinoma of endometrium, can be for the preparation of anti-endometrium cancer drug.
Claims (1)
1.Houttuynoid the application of C in treatment endometrium cancer drug, described compound H outtuynoid C-structure as
Formula IShown in:
Formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210418326.7A CN102861062B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid C in endometrial cancer treatment medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210418326.7A CN102861062B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid C in endometrial cancer treatment medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102861062A true CN102861062A (en) | 2013-01-09 |
| CN102861062B CN102861062B (en) | 2014-04-02 |
Family
ID=47440380
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210418326.7A Expired - Fee Related CN102861062B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid C in endometrial cancer treatment medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102861062B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070080329A (en) * | 2006-02-07 | 2007-08-10 | 인제대학교 산학협력단 | Composition comprising the extract of houttuynia cordata for treating or prevening cancer disease |
-
2012
- 2012-10-27 CN CN201210418326.7A patent/CN102861062B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070080329A (en) * | 2006-02-07 | 2007-08-10 | 인제대학교 산학협력단 | Composition comprising the extract of houttuynia cordata for treating or prevening cancer disease |
Non-Patent Citations (1)
| Title |
|---|
| SHAO-DAN CHEN ETAL: "Houttuynoids A-E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata", 《ORGANIC LETTERS》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102861062B (en) | 2014-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102861099B (en) | Application of Houttuynoid D in preparing medicine for treating endometrial cancer | |
| CN102861056B (en) | Application of Houttuynoid A in endometrial cancer treatment medicine | |
| CN102861062B (en) | Application of Houttuynoid C in endometrial cancer treatment medicine | |
| CN102872129B (en) | Application of Houttuynoid E in drug for treating endometrial cancer | |
| CN102861059B (en) | Application of Houttuynoid D in pancreatic cancer treatment medicine | |
| CN102872077B (en) | Application of Houttuynoid B in drugs for treating endometrial cancer | |
| CN102872076B (en) | Application of Houttuynoid A in drugs for treating tongue cancer | |
| CN102861057B (en) | Application of Houttuynoid D in skin cancer treatment medicine | |
| CN102872101B (en) | Application of Houttuynoid C in medicine for treating ileocecum cancer | |
| CN102861050A (en) | Application of Houttuynoid A in medicine for treating pancreatic cancer | |
| CN102872109B (en) | Application of Houttuynoid A in medicament for treating prostate cancer | |
| CN102872150B (en) | Application of Houttuynoid B in medicament for treating prostatic cancer | |
| CN102872070B (en) | Application of Houttuynoid C to preparing drugs for treating prostate cancer | |
| CN102861048A (en) | Application of Houttuynoid A in medicine for treating nasopharyngeal carcinoma | |
| CN102861046A (en) | Application of Houttuynoid A in ovarian cancer treatment medicine | |
| CN102861052A (en) | Application of Houttuynoid A in medicine for treating ileocecum cancer | |
| CN102861051A (en) | Application of Houttuynoid A in medicine for treating renal cancer | |
| CN102872139A (en) | Application of Houttuynoid C in drug for treating tongue cancer | |
| CN103120684A (en) | Application of Aphanamixoid A in medicine for treating endometrial carcinoma | |
| CN102872103A (en) | Application of Houttuynoid E in medicine for treating nasopharyngeal carcinoma | |
| CN102872073A (en) | Application of Houttuynoid C in drugs for treating ovarian cancer | |
| CN102861049A (en) | Application of Houttuynoid A in medicine for treating liver cancer | |
| CN102861080A (en) | Application of Houttuynoid C in medicine for treating nasopharynx cancer | |
| CN102861058A (en) | Application of Houttuynoid D in cholangiocarcinoma treatment medicine | |
| CN102895247A (en) | Application of Houttuynoid B to medicament for treating oophoroma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: WUXI HUAQI BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: WU JUNHUA Effective date: 20131217 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Li Hua Inventor before: Wu Junyi Inventor before: Feng Yi Inventor before: Wu Junhua |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: WU JUNYI FENG YI WU JUNHUA TO: LI HUA Free format text: CORRECT: ADDRESS; FROM: 210009 NANJING, JIANGSU PROVINCE TO: 214000 WUXI, JIANGSU PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20131217 Address after: 214000, No. 2, Hsinchu Road, Yunlin street, Xishan economic and Technological Development Zone, Xishan District, Jiangsu, Wuxi Applicant after: WUXI HUAQI BIOLOGICAL TECHNOLOGY CO., LTD. Address before: 210009 No. 22, Hankou Road, Gulou District, Jiangsu, Nanjing Applicant before: Wu Junhua |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140402 Termination date: 20171027 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |